A Phase 2, Proof of Concept, Randomized, Open-Label, Two-Arm, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of FK778 Compared With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy
Latest Information Update: 13 Jun 2012
At a glance
- Drugs FK 778 (Primary)
- Indications Human polyomavirus infections; Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 06 Jun 2012 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
- 22 Dec 2005 New trial record.